Mirror Biologics, Inc. Closes Out $30M Series A Investment Round with Additional $20M
Mirror Biologics, Inc., a clinical-stage biopharmaceutical company today announced the completion of the final $20 million tranche of its $30 million Series A investment round with Hong-based Bradbury Asset Management Limited.…
Continue Reading
Mirror Biologics, Inc. Closes Out $30M Series A Investment Round with Additional $20M